BIOSTAR PHARM-B

2563
3.4900.00% ( 0.000 )
Delay Closed: Nov 16, 16:08:00

Profile

About

BIOSTAR PHARM-B
BIOSTAR PHARM-B
02563.HK

Beijing Biostar Pharmaceuticals Co., Ltd., a synthetic biology-driven biopharmaceutical company, engages in the development, manufacturing, and commercialization of oncology products in the People’s Republic of China. The company develops Utidelone injections for metastatic breast cancer, breast cancer neoadjuvant, non-small cell lung cancer, pancreatic cancer, non-small cell lung cancer brain metastasis, and breast cancer brain metastasis indications; and Utidelone capsules for metastasis breast cancer, triple-negative breast cancer adjuvant intensive, first line gastric cancer, platinum-resistant ovarian cancer, and soft tissue sarcoma indications. It is also involved in the development of Utidelone antibody drug conjugate in preclinical studies; and BG22, BG18, and BG44 products for solid tumor indications in preclinical studies. Beijing Biostar Pharmaceuticals Co., Ltd.

Profile

Company Name
Beijing Biostar Pharmaceuticals Co., Ltd.
Market
SEHK
Founded
Industry
--
Fiscal Year End
December 31

Related Securities

Industry

Management